HER2 in Stemness and Epithelial-mesenchymal Plasticity of Breast Cancer

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2018 Oct 12

PMID 30306401

Citations 13

Authors

I A Voutsadakis

Affiliations

Soon will be listed here.

Abstract

Breast cancer had been the first non-hematologic malignancy where sub-types based on molecular characterization had entered clinical practice. HER2 over-expression, due to either gene amplification or protein up-regulation, defines one of these sub-types and is clinically exploited by addition of HER2-targeted treatments to the regimens of treatment. Nevertheless, in many occasions HER2-positive cancers are resistant or become refractory to these therapies. Several mechanisms, such as activation of alternative pathways or loss of expression of the receptor in cancer cells, have been proposed as the cause of these therapeutic failures. Cancer stem cells (CSCs, alternatively called tumor-initiating cells) comprise a small percentage of the tumor cells, but are capable of reconstituting and propagating tumors due to their superior intrinsic capacity for regeneration, survival and resistance to therapies. CSCs possess circuits enabling epigenetic plasticity which endow them with the ability to alternate between epithelial and mesenchymal states. This paper will discuss the expression and regulation of HER2 in CSCs of the different sub-types of breast cancer and relationships of the receptor with both the circuits of stemness and epithelial-mesenchymal plasticity. Therapeutic repercussions of the relationship of HER2-initiated signaling with stemness networks will also be proposed.

Citing Articles

Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer.

Marei H, Bedair K, Hasan A, Al-Mansoori L, Caratelli S, Sconocchia G Cancer Cell Int. 2025; 25(1):3.

PMID: 39755633 PMC: 11700463. DOI: 10.1186/s12935-024-03615-8.

formula enhances the inhibitory effects of trastuzumab on HER2-positive breast cancer.

Li F, Wu Y, Shi Y, Liu X, Xie Y, Liu S Acta Biochim Biophys Sin (Shanghai). 2024; 56(3):462-473.

PMID: 38379418 PMC: 11292138. DOI: 10.3724/abbs.2023281.

EMT Features in Claudin-Low versus Claudin-Non-Suppressed Breast Cancers and the Role of Epigenetic Modifications.

Voutsadakis I Curr Issues Mol Biol. 2023; 45(7):6040-6054.

PMID: 37504297 PMC: 10378159. DOI: 10.3390/cimb45070381.

Comparison of Clinical Subtypes of Breast Cancer within the Claudin-Low Molecular Cluster Reveals Distinct Phenotypes.

Voutsadakis I Cancers (Basel). 2023; 15(10).

PMID: 37345027 PMC: 10216296. DOI: 10.3390/cancers15102689.

Characteristics and Prognosis of 8p11.23-Amplified Squamous Lung Carcinomas.

Voutsadakis I J Clin Med. 2023; 12(5).

PMID: 36902501 PMC: 10002535. DOI: 10.3390/jcm12051711.

References

Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H . Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19):10869-74. PMC: 58566. DOI: 10.1073/pnas.191367098. View

Timmerman L, Grego-Bessa J, Raya A, Bertran E, Perez-Pomares J, Diez J . Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 2004; 18(1):99-115. PMC: 314285. DOI: 10.1101/gad.276304. View

Braun S, Vogl F, Naume B, Janni W, Osborne M, Coombes R . A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005; 353(8):793-802. DOI: 10.1056/NEJMoa050434. View

Becker S, Becker-Pergola G, Fehm T, Wallwiener D, Solomayer E . Her2 expression on disseminated tumor cells from bone marrow of breast cancer patients. Anticancer Res. 2005; 25(3B):2171-5. View

Tan M, Li P, Sun M, Yin G, Yu D . Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene. 2006; 25(23):3286-95. DOI: 10.1038/sj.onc.1209361. View

Liu X, Fridman J, Wang Q, Caulder E, Yang G, Covington M . Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. Cancer Biol Ther. 2006; 5(6):648-56. DOI: 10.4161/cbt.5.6.2707. View

Qian L, Chen L, Shi M, Yu M, Jin B, Hu M . A novel cis-acting element in Her2 promoter regulated by Stat3 in mammary cancer cells. Biochem Biophys Res Commun. 2006; 345(2):660-8. DOI: 10.1016/j.bbrc.2006.04.153. View

Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G . Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 2006; 12(19):5615-21. DOI: 10.1158/1078-0432.CCR-06-0169. View

Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J . Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007; 99(8):628-38. DOI: 10.1093/jnci/djk134. View

10.

Voutsadakis I . Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2. J Cell Mol Med. 2007; 11(2):252-85. PMC: 3822826. DOI: 10.1111/j.1582-4934.2007.00032.x. View

11.

Magnifico A, Albano L, Campaner S, Campiglio M, Pilotti S, Menard S . Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification. Cancer Res. 2007; 67(11):5308-17. DOI: 10.1158/0008-5472.CAN-06-3936. View

12.

Leong K, Niessen K, Kulic I, Raouf A, Eaves C, Pollet I . Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med. 2007; 204(12):2935-48. PMC: 2118507. DOI: 10.1084/jem.20071082. View

13.

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K . Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131(5):861-72. DOI: 10.1016/j.cell.2007.11.019. View

14.

Paik S, Kim C, Wolmark N . HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008; 358(13):1409-11. DOI: 10.1056/NEJMc0801440. View

15.

Ginestier C, Hur M, Charafe-Jauffret E, Monville F, Dutcher J, Brown M . ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2008; 1(5):555-67. PMC: 2423808. DOI: 10.1016/j.stem.2007.08.014. View

16.

Osipo C, Patel P, Rizzo P, Clementz A, Hao L, Golde T . ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene. 2008; 27(37):5019-32. DOI: 10.1038/onc.2008.149. View

17.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

18.

Korkaya H, Paulson A, Iovino F, Wicha M . HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene. 2008; 27(47):6120-30. PMC: 2602947. DOI: 10.1038/onc.2008.207. View

19.

Morel A, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A . Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One. 2008; 3(8):e2888. PMC: 2492808. DOI: 10.1371/journal.pone.0002888. View

20.

Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P . Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin Cancer Res. 2009; 15(6):2010-21. DOI: 10.1158/1078-0432.CCR-08-1327. View